Clinical trial NCT06949826: Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery
Official title: A Single-institution, Parallel, Double-blinded, Randomized Study Assessing the Safety and Efficacy of Transdermal Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Pain, Postoperative
Ankle Fracture Surgery
Opioid Use Disorder
Opioid Dependence
Opioid Analgesia
Keywords: Buprenorphine
Postoperative pain
Transdermal buprenorphine
Ankle fracture surgery
Ankle fracture
Opioid-naive patient
ORIF Ankle Fracture
Opioid use disorder
Opioid Addiction
Buprenorphine for postoperative pain
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: The Foundation for Barnes-Jewish Hospital
name: Washington University Institute of Clinical and Translational Sciences
First posted: 2025-04-29
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Addictive full-agonist opioids, like oxycodone and hydrocodone, are often used to treat pain after surgery. However, these full-agonist opioids can be very addictive. After ankle fracture surgery, about 1 in 5 patients that did not take opioids before surgery become addicted to opioids after surgery. Buprenorphine is an opioid with unique properties that may offer a way to reduce the number of patients that become addicted to opioids after surgery. Buprenorphine has good analgesic (painkilling) effects. It is also thought to be less addictive and cause less of a high than full-agonist opioids, like oxycodone and hydrocodone. This project's goal is to determine if transdermal buprenorphine can safely and effectively control pain after ankle fracture surgery. This study will be a pilot study, which sets the stage for future studies that investigate whether buprenorphine can reduce the rate that patients become addicted to opioids after surgery. This study's multidisciplinary team will divide patients into two groups. Participants in one group will be treated with a 7-day transdermal buprenorphine patch (where the buprenorphine is slowly absorbed through the skin over 7 days). Participants in the other group will be treated with a placebo patch. A placebo has no drug in it, it just looks like the buprenorphine patch. Aside from the buprenorphine patch or placebo patch, both groups' pain management plans will be the same as if they were not in the study. Over the first week after surgery, the investigators will measure the amount of full-agonist opioids (for example, oxycodone or hydrocodone) that participants consume, participants' pain scores, the frequency of side effects related to opioids, and the number of calls and patient portal messages to the clinic for uncontrolled pain. The investigators will also assess whether participants are continuing to use opioids 3 months after surgery for pain related to their ankle fracture.

Detailed description: Addictive full-agonist opioids, like oxycodone, remain a staple of post-operative analgesia after many types of surgery. However, perioperative exposure to opioid analgesics risks addiction in up to 7% of cases. Moreover, opioid overdoses kill over 80,000 in the United States (US) annually. Buprenorphine, a partial-agonist of the μ-opioid receptor and an antagonist of the κ-opioid receptor, may be able to safely function as a post-operative analgesic, reducing our reliance on full-agonist opioids post-operatively. Compared to full-agonist opioids, buprenorphine has a favorable safety profile. It has been hypothesized that buprenorphine's unique pharmacodynamics give it a lower addictive potential compared to full-agonist opioids. Moreover, it endows a ceiling on respiratory depression, has reduced dysphoric and psychotomimetic effects, and does not result in immunosuppression at therapeutic analgesic doses. International studies have suggested that transdermal buprenorphine is noninferior to tramadol, transdermal fentanyl, and oral celecoxib in the management of acute post-operative pain in opioid-naïve patients following orthopaedic surgery. However, the efficacy of buprenorphine for postoperative analgesia has never been studied in the United States, whose population has different beliefs and expectations surrounding pain control when compared to international populations. The major goal of this project is to determine the safety and efficacy of transdermal buprenorphine for postoperative analgesia, as a first step toward exploring the ability of buprenorphine to mitigate the incidence of opioid dependence in the postoperative setting.

This study will assess whether buprenorphine can reduce the use of full-agonist opioids following ankle fracture surgery. Approximately one in five opioid-naïve patients undergoing ankle fracture surgery continue to use opioids 3 to 6 months out from surgery, suggesting that this population is relatively susceptible to developing post-operative opioid dependence. The investigators will divide patients into two groups. One group will be treated with a 7-day transdermal buprenorphine patch. The other will be treated with a placebo patch. Both groups will otherwise receive a post-operative pain management regimen that is in accordance with the standard of care. The investigators hypothesize that participants treated with the buprenorphine patch will experience improved analgesia with the use fewer full-agonist opioids following ankle fracture surgery than those treated with the placebo patch. This hypothesis will be tested with the following aims.

Specific Aim 1: To measure the analgesic effect of buprenorphine on post-operative analgesia. In this Aim, the investigators will test the hypothesis that use of buprenorphine patches will reduce the average pain scores and consumption of full-agonist opioids after ankle fracture surgery. In sub-Aim 1.1, the investigators will quantify postoperative pain by monitoring participants' visual analog scale pain scores and full-agonist opioid consumption over the first post-operative week. In sub-Aim 1.2, the investigators will track the number of episodes of breakthrough pain in the hospital, the number of calls to the clinic with a chief complaint of uncontrolled pain, and the number of presentations to an emergency department for uncontrolled surgery-related pain.

Specific Aim 2: To examine the safety of buprenorphine as a post-operative analgesic following ankle fracture surgery. In this Aim, the investigators will test the hypothesis that participants treated with buprenorphine patches will experience fewer adverse events related to opioid exposure compared to those treated with placebo patches. The investigators will monitor for adverse effects of buprenorphine and full-agonist opioids, including respiratory depression, constipation, nausea, and vomiting. The investigators will track the number of presentations to an emergency department with a diagnosis of opioid toxicity. For pilot data, the investigators will also monitor use of opioids for analgesia at the 3-month postoperative time point as a secondary outcome.

This study assesses whether buprenorphine safely reduces full-agonist opioid use after orthopaedic surgery. Completion of the Aims of this study will permit future studies assessing whether buprenorphine comprises a less-addictive alternative for postoperative analgesia compared to full-agonist opioids. Annually, there are 40-50 million major surgeries performed in the US. As 6-7% of opioid-naïve patients develop long-term opioid use after major surgery, exploring avenues to decrease the impact of post-operative analgesia on the opioid epidemic is critical.

Eligibility criteria: INCLUSION CRITERIA:

* Patient is 18 years of age or older
* Patient is undergoing single stage ORIF of an ankle fracture
* Patient is English-speaking

EXCLUSION CRITERIA:

* Patient is under 18 years of age
* Patient's ankle fracture is treated with external fixation
* Patient has a concomitant osseous or visceral injury
* Patient has a history of opioid use disorder or a current diagnosis of opioid use disorder
* Patient has a history of alcohol use disorder or a current diagnosis of alcohol use disorder
* Patient was taking opioid medication or narcotic drugs prior to their injury
* Patient has a current active malignancy
* Patient is taking a medication that carries a prohibitively high risk of drug-drug interaction with buprenorphine, hydrocodone, or oxycodone in the view of their treating physician or nurse anesthetist
* Patient has an anaphylactic allergy to buprenorphine, hydrocodone, or oxycodone
* Patient is not English-speaking
* Patient is pregnant
* Patient is unable to complete pain diary or communicate pain scores
* Patient is incarcerated
* Patient has a Gustilo-Anderson Type III open fracture

Primary outcomes:
measure: Visual Analog Pain Scores
timeFrame: Postoperative days 1-8, 21, 90.
measure: Morphine Milligram Equivalents of Full-agonist Opioid Consumed
timeFrame: Post-operative days 0-7. First post-operative clinic visit (approximately 3 weeks after surgery).
measure: Hospital Readmissions due to Opioid Toxicity
timeFrame: From patch application to post-operative day 21
measure: Emergency Department Presentations due to Opioid Toxicity
timeFrame: From patch application to post-operative day 21
measure: Emergency Department Presentations due to Uncontrolled Pain
timeFrame: From patch application through post-operative day 21.
measure: Hospital Readmissions due to Uncontrolled Post-operative Pain
timeFrame: From patch application through post-operative day 21.
measure: Adverse Effects Related to Opioid Medication
timeFrame: Post-operative days 1-8, 21.
Secondary outcomes:
measure: Morphine Milligram Equivalents of Full-Agonist Opioids Administered in Perioperative Setting
timeFrame: Perioperative/Periprocedural
measure: Time from Surgery Completion to Discharge
timeFrame: Perioperative/periprocedural
measure: Hospital Length of Stay
timeFrame: From the completion of ankle fracture surgery to hospital discharge.
measure: Number of Breakthrough Pain Episodes while Inpatient
timeFrame: Post-operative day 0 through hospital discharge
measure: Quality of Recovery after Anesthesia 15-Question Survey
timeFrame: Post-operative day 7
measure: Telephone Calls and MyChart Messages to Clinic or Call Center with a Chief Complaint of Uncontrolled Pain
timeFrame: Post-operative days 0-21.
measure: Opioid Medication Prescriptions - Number and Total Morphine Milligram Equivalents Prescribed
timeFrame: From the time of injury through post-operative day 90.
measure: Drug Liking and Economic Choice Survey
timeFrame: Post-operative days 7, 21, 90
measure: Patient Satisfaction with Post-operative Pain Control
timeFrame: Post-operative days 7, 21
measure: Rate of Persistent Opioid Use
timeFrame: Post-operative day 90
measure: Prescription Pain Medication Misuse Short Form 7a Scores
timeFrame: Post-operative day 90
measure: Post-operative Complication Rate
timeFrame: Post-operative days 0-90
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University in St. Louis/Barnes Jewish Hospital
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Jenna Wilson, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lawal OD, Gold J, Murthy A, Ruchi R, Bavry E, Hume AL, Lewkowitz AK, Brothers T, Wen X. Rate and Risk Factors Associated With Prolonged Opioid Use After Surgery: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Jun 1;3(6):e207367. doi: 10.1001/jamanetworkopen.2020.7367.
citation: Vadivelu N, Hines RL. Buprenorphine: a unique opioid with broad clinical applications. J Opioid Manag. 2007 Jan-Feb;3(1):49-58. doi: 10.5055/jom.2007.0038.
citation: Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978 Apr;35(4):501-16. doi: 10.1001/archpsyc.1978.01770280111012.
citation: Walsh SL, Babalonis S. The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research. Curr Top Behav Neurosci. 2017;34:33-58. doi: 10.1007/7854_2016_448.
citation: Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994 May;55(5):569-80. doi: 10.1038/clpt.1994.71.
citation: Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009 Mar;13(3):219-30. doi: 10.1016/j.ejpain.2008.04.011. Epub 2008 Jun 24.
citation: Pergolizzi JV Jr, Magnusson P, LeQuang JA, Breve F, Mitchell K, Chopra M, Varrassi G. Transdermal Buprenorphine for Acute Pain in the Clinical Setting: A Narrative Review. J Pain Res. 2021 Mar 31;14:871-879. doi: 10.2147/JPR.S280572. eCollection 2021.
citation: Desai SN, Badiger SV, Tokur SB, Naik PA. Safety and efficacy of transdermal buprenorphine versus oral tramadol for the treatment of post-operative pain following surgery for fracture neck of femur: A prospective, randomised clinical study. Indian J Anaesth. 2017 Mar;61(3):225-229. doi: 10.4103/ija.IJA_208_16.
citation: Arshad Z, Prakash R, Gautam S, Kumar S. Comparison between Transdermal Buprenorphine and Transdermal Fentanyl for Postoperative Pain Relief after Major Abdominal Surgeries. J Clin Diagn Res. 2015 Dec;9(12):UC01-4. doi: 10.7860/JCDR/2015/16327.6917. Epub 2015 Dec 1.
citation: Kim HJ, Ahn HS, Nam Y, Chang BS, Lee CK, Yeom JS. Comparative study of the efficacy of transdermal buprenorphine patches and prolonged-release tramadol tablets for postoperative pain control after spinal fusion surgery: a prospective, randomized controlled non-inferiority trial. Eur Spine J. 2017 Nov;26(11):2961-2968. doi: 10.1007/s00586-017-5213-5. Epub 2017 Jul 20.
citation: Londhe S, Patwardhan M, Shah R, Oak M. Efficacy and Safety of Buprenorphine Transdermal Patch for Immediate Postoperative Analgesia After Total Knee Arthroplasty Surgery. J Arthroplasty. 2020 Jun;35(6S):S178-S181. doi: 10.1016/j.arth.2020.02.015. Epub 2020 Feb 13.
citation: Londhe SB, Patwardhan M, Shah RV, Oak M, Shah A, Antao N, Khot R. Comparison of Efficacy and Safety of Transdermal Buprenorphine Patch and Conventional Analgesics in Intra-capsular Femur Neck Fracture Post Hemiarthroplasty. Indian J Orthop. 2022 Jun 25;56(8):1363-1369. doi: 10.1007/s43465-022-00668-7. eCollection 2022 Aug.
citation: Niyogi S, Bhunia P, Nayak J, Santra S, Acharjee A, Chakraborty I. Efficacy of transdermal buprenorphine patch on post-operative pain relief after elective spinal instrumentation surgery. Indian J Anaesth. 2017 Nov;61(11):923-929. doi: 10.4103/ija.IJA_118_17.
citation: Setti T, Sanfilippo F, Leykin Y. Transdermal buprenorphine for postoperative pain control in gynecological surgery: a prospective randomized study. Curr Med Res Opin. 2012 Oct;28(10):1597-608. doi: 10.1185/03007995.2012.719864. Epub 2012 Sep 10.
citation: Xu X, Xie L, Liu H, Hu Y. Transdermal buprenorphine patch versus oral celecoxib for pain management after total knee arthroplasty: An open- label, randomized controlled trial. Orthop Traumatol Surg Res. 2020 Sep;106(5):915-919. doi: 10.1016/j.otsr.2020.04.010. Epub 2020 Jul 2.
citation: Burden M, Keniston A, Wallace MA, Busse JW, Casademont J, Chadaga SR, Chandrasekaran S, Cicardi M, Cunningham JM, Filella D, Hoody D, Hilden D, Hsieh MJ, Lee YS, Melley DD, Munoa A, Perego F, Shu CC, Sohn CH, Spence J, Thurman L, Towns CR, You J, Zocchi L, Albert RK. Opioid Utilization and Perception of Pain Control in Hospitalized Patients: A Cross-Sectional Study of 11 Sites in 8 Countries. J Hosp Med. 2019 Dec 1;14(12):737-745. doi: 10.12788/jhm.3256. Epub 2019 Jul 24.
citation: Otwell AG, Stambough JB, Cherney SM, Blake L, Siegel ER, Mears SC. Does the type of lower extremity fracture affect long-term opioid usage? A meta-analysis. Arch Orthop Trauma Surg. 2024 Mar;144(3):1221-1231. doi: 10.1007/s00402-023-05174-5. Epub 2024 Feb 16.
citation: Skibicki H, Saini S, Rogero R, Nicholson K, Shakked RJ, Fuchs D, Winters BS, Raikin SM, Pedowitz DI, Daniel JN. Opioid Consumption Patterns and Prolonged Opioid Use Among Opioid-Naive Ankle Fracture Patients. Foot Ankle Spec. 2023 Feb;16(1):36-42. doi: 10.1177/1938640021992922. Epub 2021 Feb 12.
citation: Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011 Mar;4(1):28-41. doi: 10.2174/1874473711104010028.
citation: Carl P, Crawford ME, Madsen NB, Ravlo O, Bach V, Larsen AI. Pain relief after major abdominal surgery: a double-blind controlled comparison of sublingual buprenorphine, intramuscular buprenorphine, and intramuscular meperidine. Anesth Analg. 1987 Feb;66(2):142-6.
citation: Dobkin AB, Esposito B, Philbin C. Double-blind evaluation of buprenorphine hydrochloride for post-operative pain. Can Anaesth Soc J. 1977 Mar;24(2):195-202. doi: 10.1007/BF03006232.
citation: Chakravarty K, Tucker W, Rosen M, Vickers MD. Comparison of buprenorphine and pethidine given intravenously on demand to relieve postoperative pain. Br Med J. 1979 Oct 13;2(6195):895-7. doi: 10.1136/bmj.2.6195.895.
citation: Tigerstedt I, Tammisto T. Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain. Acta Anaesthesiol Scand. 1980 Dec;24(6):462-8. doi: 10.1111/j.1399-6576.1980.tb01584.x.
citation: Masson AH. Sublingual buprenorphine versus oral dihydrocodeine in post-operative pain. J Int Med Res. 1981;9(6):506-10. doi: 10.1177/030006058100900614.
citation: Mok MS, Lippmann M, Steen SN. Multidose/observational, comparative clinical analgetic evaluation of buprenorphine. J Clin Pharmacol. 1981 Jul;21(7):323-9. doi: 10.1002/j.1552-4604.1981.tb01774.x.
citation: Ouellette RD. Buprenorphine and morphine efficacy in postoperative pain: a double-blind multiple-dose study. J Clin Pharmacol. 1982 Apr;22(4):165-72. doi: 10.1002/j.1552-4604.1982.tb02158.x.
citation: Freedman M. A comparison of buprenorphine and pentazocine for the relief of postoperative pain. S Afr Med J. 1986 Jan 4;69(1):27-8.
citation: Maunuksela EL, Korpela R, Olkkola KT. Comparison of buprenorphine with morphine in the treatment of postoperative pain in children. Anesth Analg. 1988 Mar;67(3):233-9.
citation: Maunuksela EL, Korpela R, Olkkola KT. Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain of children. Br J Anaesth. 1988 Jan;60(1):48-55. doi: 10.1093/bja/60.1.48.
citation: Dingus DJ, Sherman JC, Rogers DA, DiPiro JT, May R, Bowden TA Jr. Buprenorphine versus morphine for patient-controlled analgesia after cholecystectomy. Surg Gynecol Obstet. 1993 Jul;177(1):1-6.
citation: Khandelwal H, Negi A, Govil N, Singh A, Parag K, Bhardwaj BB. Comparative evaluation of analgesic efficacy of buprenorphine transdermal patch and fentanyl patch in management of postoperative pain after arthroscopic lower limb surgery: A randomized controlled trial. J Anaesthesiol Clin Pharmacol. 2021 Apr-Jun;37(2):272-278. doi: 10.4103/joacp.JOACP_405_20. Epub 2021 Jul 15.
citation: Lee JH, Kim JH, Kim JH, Kim HS, Min WK, Park YS, Lee KY, Lee JH. Efficacy and Safety of Transdermal Buprenorphine versus Oral Tramadol/Acetaminophen in Patients with Persistent Postoperative Pain after Spinal Surgery. Pain Res Manag. 2017;2017:2071494. doi: 10.1155/2017/2071494. Epub 2017 Sep 13.